Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant immunotoxins

I Pastan1, L H Pai, U Brinkmann

  • 1Laboratory of Molecular Biology, DCBDC, National Cancer Institute, NIH, Bethesda, MD, USA.

Breast Cancer Research and Treatment
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disentangling Centrality Bias and Final-State Effects in the Production of High-p_{T} Neutral Pions Using Direct Photon in d+Au Collisions at sqrt[s_{NN}]=200  GeV.

Physical review letters·2025
Same author

Dapsone Induced Methaemoglobinaemia A reminder the iatrogenic causes of cyanosis.

Irish medical journal·2023
Same author

Measurement of Direct-Photon Cross Section and Double-Helicity Asymmetry at sqrt[s]=510  GeV in p[over →]+p[over →] Collisions.

Physical review letters·2023
Same author

Is perinatal substance abuse falling through the cracks?

Irish journal of psychological medicine·2023
Same author

Examining the impact of premature birth on parental mental health and family functioning in the years following hospital discharge: A review.

Journal of neonatal-perinatal medicine·2023
Same author

Probing Gluon Spin-Momentum Correlations in Transversely Polarized Protons through Midrapidity Isolated Direct Photons in p^{↑}+p Collisions at sqrt[s]=200  GeV.

Physical review letters·2021
Same journal

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Breast cancer research and treatment·2026
Same journal

Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.

Breast cancer research and treatment·2026
Same journal

Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.

Breast cancer research and treatment·2026
Same journal

Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

Breast cancer research and treatment·2026
Same journal

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Breast cancer research and treatment·2026
Same journal

Subjective socioeconomic status moderates the relationship between objective neighborhood disadvantage and quality of life in middle- and older-aged women with breast cancer.

Breast cancer research and treatment·2026
See all related articles

Genetically modified Pseudomonas exotoxin targets cancer cells by replacing its binding domain with cancer-specific antibody fragments. These novel recombinant immunotoxins are advancing through clinical trials for various cancers.

Area of Science:

  • Biotechnology
  • Oncology
  • Immunology

Background:

  • Pseudomonas exotoxin is a potent toxin with cytotoxic properties.
  • Targeting cancer cells specifically remains a challenge in cancer therapy.
  • Genetically engineered toxins can offer targeted cancer treatment strategies.

Purpose of the Study:

  • To engineer Pseudomonas exotoxin for targeted cancer cell destruction.
  • To develop novel recombinant immunotoxins for cancer therapy.
  • To evaluate the potential of antibody-targeted toxins in clinical settings.

Main Methods:

  • Genetic modification of Pseudomonas exotoxin by deleting its native cell-binding domain.
  • Fusion of the modified exotoxin with Fv fragments of antibodies specific to cancer antigens.

Related Experiment Videos

  • Development of recombinant immunotoxins targeting breast, colon, and other cancer types.

    • Main Results:

    • Successfully created genetically modified Pseudomonas exotoxin derivatives.
    • Developed immunotoxins capable of targeting specific cancer cell types.
    • Initiated clinical trials for several recombinant immunotoxin candidates.

    Conclusions:

    • Genetically engineered Pseudomonas exotoxin shows promise for targeted cancer therapy.
    • Recombinant immunotoxins represent a viable strategy for developing novel anti-cancer agents.
    • Ongoing clinical trials will further define the efficacy and safety of these targeted toxins.